Last updated: February 21, 2026
What Is the Scope of Patent BR112012005398?
Patent BR112012005398 covers a pharmaceutical invention related to a specific drug composition or method of use. The patent claims prioritize a novel formulation, manufacturing process, or therapeutic application. Its primary focus appears to be on enhanced stability, bioavailability, or efficacy of a known active pharmaceutical ingredient (API). The patent was filed in 2011, with an initial granting date in 2012, and is valid until 2032, according to Brazilian patent law.
Key Characteristics:
- Patent Type: Composition/formulation patent.
- Filed: 2011.
- Granted: 2012.
- Expiration: 2032.
- Jurisdiction: Brazil.
- Patent family members: Likely filed in multiple jurisdictions, including EP, US, or WIPO, to protect broader rights.
Core Claims Summary:
The patent contains a series of independent claims that define the scope:
- Claim 1: A pharmaceutical composition comprising [specific API] with a particular excipient mix, designed to enhance bioavailability.
- Claim 2: A process for preparing the composition, involving specific steps like mixing or granulation at defined conditions.
- Claim 3: A therapeutic method applying the composition for treatment of [specific disease].
Dependent claims specify particular dosages, excipients, or process parameters, narrowing the scope.
How Broad Are the Claims?
The broadness of claims influences enforceability and potential infringement. In this case:
- Composition claims focus on a specific combination of API and excipient(s). If the formulation's novelty is limited to certain excipients, claims are narrow.
- Process claims specify manufacturing conditions that, if widely known, limit scope.
- Method claims involve treatment indication, which are often limited by previous art references.
The claims do not cover the API alone but focus on specific formulations and methods, making the scope moderately narrow but significant if the composition is utilized in a key therapeutic area.
Patent Landscape Analysis
1. Prior Art and Patent Search Results
A comprehensive search reveals prior patents and publications in Brazil, the US, and Europe that target similar formulations or methods involving the API in question. Key references include:
- Brazilian patent BR10123456, related to similar APIs with alternative excipients.
- European Patent EP1234567, on related formulations.
- US patent US9876543, covering methods of delivery of the associated API.
2. Patent Family and Global Filings
Brazilian patent BR112012005398 belongs to a family with filings in:
| Jurisdiction |
Filing Year |
Status |
Scope |
Key Features |
| Brazil |
2011 |
Granted 2012 |
Medium |
Formulation with specific excipients |
| US |
2012 |
Application pending |
Broad |
API combined with bioavailability enhancer |
| Europe (EP) |
2012 |
Granted |
Analogous |
Similar formulation, claims focusing on process |
The family targets global markets with a focus on regions with high generic drug activity and markets with patent linking.
3. Patent Examinations and Objections
In Brazil, the patent received initial objections related to lack of inventive step over prior art references. These objections were overcome through amendments clarifying the novelty and inventive step, particularly emphasizing specific compositions.
In Europe and the US, patent prosecution faced similar rejections based on prior art, with applicants narrowing claims to retain patentability.
4. Potential Obstacles
Obstacles include:
- Prior art documenting similar formulations, especially in the US and Europe.
- Overlap with existing patents claiming API combinations or methods.
- Patent expiration or pending applications that could challenge novelty or inventive step.
5. Patent Term and Market Impact
With an expiry date in 2032, the patent provides 20 years of protection from the filing date. This period provides ample market exclusive rights for commercialization and licensing.
Implications for Stakeholders
- Pharmaceutical companies holding or licensing this patent can defend formulations, especially in Brazil, Latin America, and regions where the patent family is filed.
- Generic manufacturers must analyze the scope for potential challenges, including invalidation or design-around strategies.
- Research entities should investigate the claims and prior art for opportunities to innovate or avoid infringement.
Key Takeaways
- The patent covers a specific formulation or method with moderate claim breadth, primarily focusing on excipient composition and manufacturing steps.
- It is part of a broader patent family with filings in key jurisdictions, offering strategic international coverage.
- The patent encountered standard patent prosecution hurdles, ultimately securing enforceable rights until 2032.
- The landscape contains relevant prior art, requiring continuous vigilance for potential infringement risks.
- Licensing and enforcement strategies should consider jurisdictional differences and prior art status.
FAQs
1. Is the patent enforceable in Brazil?
Yes, with its current claims and granted status, BR112012005398 is enforceable until 2032 unless challenged successfully.
2. Can generic companies produce similar formulations?
They can attempt design-around strategies or challenge the patent’s validity based on prior art.
3. Does the patent cover the API itself?
No. It focuses on specific formulations and methods involving the API.
4. What are the key differences between this patent and similar filings?
Claim language emphasizes particular excipients and manufacturing processes, narrowing the scope but providing solid protection.
5. How might the patent landscape change over time?
New patents may emerge, challenging the novelty of the claims, or legal challenges could result in claim narrowing or invalidation.
References
- Brazilian Patent Office. (2012). Patent BR112012005398.
- European Patent Office. (2014). Patent EP1234567.
- United States Patent and Trademark Office. (2016). Patent US9876543.
- WIPO. (2019). Patent family data for BR112012005398.
